LAVAL, QC, June 16 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS)
today announced that it has entered into an agreement with Debiopharm S.A.
under which Debiopharm has engaged Labopharm to conduct research on the
potential oral delivery of a current intravenous cancer drug using Labopharm's
proprietary polymeric nano- delivery systems technology (also referred to as
"Following on the success of our patented Contramid(R) delivery
technology for orally administered drugs, we are very pleased to have advanced
our polymeric nano-delivery systems technology to the point of attracting our
first partnership," said James R. Howard-Tripp, President and Chief Executive
Officer, Labopharm Inc. "It has always been our long-term strategy to build a
specialty pharmaceutical company based on integrated drug delivery platforms.
Our core platform, Contramid(R), addresses very soluble to relatively
insoluble compounds, which comprise the majority of drugs. With our polymeric
nano-delivery system technology we can now address the delivery challenges of
water insoluble compounds, as well as, potentially, proteins and peptides."
Labopharm's polymeric nano-delivery systems are composed of proprietary,
low cost, block co-polymers developed specifically for effective delivery of
water insoluble compounds and poorly bio-available compounds, including highly
toxic compounds, such as cancer drugs. Suitable for oral and parenteral
administration, these high capacity, biocompatible and biodegradable carriers
are designed to maximize drug efficacy and to avoid many of the dose-limiting
side effects of conventional approaches. With applications in oncology,
immunology and a variety of other therapeutic arenas, polymeric nano-delivery
systems are expected to facilitate the delivery of both small molecules and
emerging drug classes such as proteins, peptides and nucleic acids.
About Debiopharm S.A.
Debiopharm, founded in 1979 in Lausanne, Switzerland, focuses on
evaluating compounds with promising in-vivo results in animals, to in-license,
develop for global registration, and out-license to sales and marketing
pharmaceutical partners. Debiopharm's major commercial successes to date are
Eloxatin(R), one of Sanofi-Synthelabo's leading marketed products,
Decapeptyl(R), the leading product of Ipsen in Southern Europe, and
Trelstar(R), with combined sales estimated to be in excess of $1.8bn in 2004.
Debiopharm is one of an established group of three complementary companies,
Debiopharm, Debio R.P. and Debioclinic, with a successful track record in
developing, registering and out-licensing innovative therapeutics. Debio R.P.
is a leader in polymer-based controlled release technologies that allow
certain drugs like proteins, peptides and anti-cancers to be delivered in
customised, sustained-release formulation. From its FDA-inspected
manufacturing facility in Martigny, Switzerland, Debio R.P. also conducts
feasibility studies, formulation selection, optimisation, scale-up and cGMP
manufacturing from clinical trial supplies to commercial scale. Debioclinic is
a contract research organisation, specialised in oncology and dedicated to
clinical development, providing regulatory, biometric and clinical support in
line with cGCP. For more information on Debiopharm, visit the company's
website at www.debio.com
About Labopharm Inc.
Labopharm Inc. (TSX:DDS) is an international specialty pharmaceutical
company focused on the development of drugs incorporating the Company's
proprietary advanced controlled-release technology, Contramid(R). Contramid(R)
can be applied to a wide variety of drugs in solid oral dosage form, improving
their oral administration and performance and is used to develop products that
are either bio-equivalent to existing, branded products, or are new branded
products. The Company's pipeline includes a combination of both in-house and
partnered programs with products both in clinical trials and in preclinical
development. Labopharm is also developing implantable mini-tablets based on
Contramid(R) for local administration of drugs and novel polymeric nano-
delivery systems for delivery of water-insoluble and poorly bio-available
drugs. For more information, please visit www.labopharm.com.
This press release contains forward-looking statements, which reflect the
Corporation's current expectations regarding future events. The forward-
looking statements involve risks and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of factors,
including the successful and timely completion of clinical studies, the
uncertainties related to the regulatory process and the commercialization of
the drug thereafter. Investors should consult the Corporation's ongoing
quarterly filings and annual reports for additional information on risks and
uncertainties relating to these forward-looking statements. The reader is
cautioned not to rely on these forward-looking statements. The Corporation
disclaims any obligation to update these forward-looking statements.
SOURCE Labopharm Inc.